HEXACHLOROBENZENE DIFFERENTIALLY MODULATES CONVENTIONAL AND METRONOMIC THERAPY IN TRIPLE NEGATIVE BREAST CANCER CELLS

SANCHEZ YAMILA; VASQUEZ ABIGAIL; MIRET NOELIA; ROLANDELLI GABINO; COSTAS CATALINA; SAPERE LAURA; VASQUES LUCIA; RANDI ANDREA; ALEJANDRO ESPAÑOL

Congreso; LXVIII reunion anual de la Sociedad Argentina de Investigacion Clinica; 2023

The conventional therapy (CT) for triple negative breast cancer (TNBC) consists in the administration of the maximum tolerable dose of chemotherapeutic drugs, such as paclitaxel (PX) which produces several adverse effects requiring long intervals between treatment cycles to patient recovery. An alternative strategy to avoid that is metronomic therapy (MT) based on the administration of lower drug doses with short drug-free intervals. In this sense, our group has demonstrated the antitumor efficacy of a metronomic combination of PX and the muscarinic agonist carbachol (Carb) in breast cancer cells.Besides, the efficacy of the antitumor treatments may be modulated by environmental pollutants such as hexachlorobenzene (HCB) which has been described to reduce doxorubicin treatment efficacy in colon cancer.In this work we evaluated if HCB modulates the efficacy of PX CT and PX+Carb MT in TNBC MDA-MB231 cells.By MTT assays we determined that an environmental concentration of HCB (10-8M) did not modify the cell viability (basal:100+/-8.2%; HCB:99.8+/-5.1%) but it significantly reduced the CT effect (PX 10-7M)(CT:67.2+/-3.2%; HCB+CT:93.7+/-4.9%; p